Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term therapy for depression with trazodone.

L F Fabre, J P Feighner

    The Journal of Clinical Psychiatry
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers.

    Biopharmaceutics & drug disposition·2005
    Same author

    Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression.

    International clinical psychopharmacology·2001
    Same author

    Citalopram treatment of fluoxetine nonresponders.

    The Journal of clinical psychiatry·2001
    Same author

    A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.

    Journal of affective disorders·2000
    Same author

    Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

    The Journal of clinical psychiatry·2000
    Same author

    Overview of antidepressants currently used to treat anxiety disorders.

    The Journal of clinical psychiatry·2000

    Trazodone demonstrated superior efficacy compared to imipramine in treating moderate to severe depression over 12 months. Trazodone offered better outcomes with fewer anticholinergic side effects, making it a beneficial option for long-term depression management.

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology
    • Neuroscience

    Background:

    • Major depressive disorder (MDD) is a prevalent and debilitating condition.
    • Tricyclic antidepressants (TCAs) like imipramine have been standard treatments, but often have significant side effects.
    • Novel antidepressants, such as trazodone, offer alternative mechanisms of action and potentially improved side effect profiles.

    Purpose of the Study:

    • To compare the efficacy and tolerability of trazodone versus imipramine in outpatients with moderate to severe depression.
    • To evaluate long-term treatment outcomes and identify patient subgroups who may benefit most from trazodone.

    Main Methods:

    • A two-center, double-blind, randomized controlled trial involving 44 outpatients diagnosed with moderate to severe depression.

    Related Experiment Videos

  • Patients received either trazodone or imipramine for a 12-month treatment period.
  • Efficacy was assessed using the Hamilton Depression Rating Scale (HDRS) and Clinical Global Impressions (CGI) ratings. Tolerability was monitored through adverse event reporting and physical examinations.

    • Main Results:

    • Trazodone showed superior efficacy at the 12-month endpoint across all measured efficacy variables compared to imipramine.
    • The trazodone group exhibited significantly lower anxiety scores on individual HDRS items throughout the study.
    • Adverse events differed, with imipramine associated with more frequent anticholinergic effects and tremor, while trazodone led to more drowsiness. Cardiovascular and ophthalmologic parameters remained stable in both groups.

    Conclusions:

    • Trazodone is a highly effective option for the long-term treatment of moderate to severe depression.
    • Trazodone may be particularly advantageous for patients susceptible to anticholinergic side effects, such as the elderly and those with cardiovascular conditions.
    • The favorable efficacy and tolerability profile of trazodone supports its use as a primary treatment for depression.